| The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy F Gragnano, S Sperlongano, E Golia, F Natale, R Bianchi, M Crisci, ... Mediators of inflammation 2017, 2017 | 219 | 2017 |
| Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international … P Paolisso, L Bergamaschi, G Santulli, E Gallinoro, A Cesaro, F Gragnano, ... Cardiovascular Diabetology 21 (1), 77, 2022 | 94 | 2022 |
| Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects G Palmiero, A Cesaro, E Vetrano, PC Pafundi, R Galiero, A Caturano, ... International Journal of Molecular Sciences 22 (11), 5863, 2021 | 69 | 2021 |
| Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease R Galiero, A Caturano, E Vetrano, A Cesaro, L Rinaldi, T Salvatore, ... Reviews in cardiovascular medicine 22 (3), 755-768, 2021 | 60 | 2021 |
| Lipoprotein (a): a genetic marker for cardiovascular disease and target for emerging therapies A Cesaro, A Schiavo, E Moscarella, S Coletta, M Conte, F Gragnano, ... Journal of Cardiovascular Medicine 22 (3), 151-161, 2021 | 57 | 2021 |
| Beyond cholesterol metabolism: the pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term … A Cesaro, V Bianconi, F Gragnano, E Moscarella, F Fimiani, E Monda, ... Biofactors 46 (3), 367-380, 2020 | 56 | 2020 |
| Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry P Paolisso, L Bergamaschi, F Gragnano, E Gallinoro, A Cesaro, C Sardu, ... Pharmacological research 187, 106597, 2023 | 55 | 2023 |
| Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: a complex combination O Scudiero, B Lombardo, M Brancaccio, C Mennitti, A Cesaro, F Fimiani, ... International Journal of Environmental Research and Public Health 18 (3), 904, 2021 | 55 | 2021 |
| Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence A Caturano, R Galiero, PC Pafundi, A Cesaro, E Vetrano, G Palmiero, ... Diabetes research and clinical practice 178, 108959, 2021 | 52 | 2021 |
| The biological role of vitamins in athletes’ muscle, heart and microbiota M Brancaccio, C Mennitti, A Cesaro, F Fimiani, M Vano, B Gargiulo, ... International journal of environmental research and public health 19 (3), 1249, 2022 | 47 | 2022 |
| SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction R Marfella, P Paolisso, C Sardu, L Palomba, N D’Onofrio, A Cesaro, ... Critical Care 25 (1), 217, 2021 | 43 | 2021 |
| Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk A Cesaro, F Gragnano, F Fimiani, E Moscarella, V Diana, I Pariggiano, ... European Journal of Preventive Cardiology 27 (5), 556-558, 2020 | 43 | 2020 |
| Laboratory medicine: Health evaluation in elite athletes B Lombardo, V Izzo, D Terracciano, A Ranieri, C Mazzaccara, F Fimiani, ... Clinical Chemistry and Laboratory Medicine (CCLM) 57 (10), 1450-1473, 2019 | 42 | 2019 |
| Impact of lipoprotein (a) levels on recurrent cardiovascular events in patients with premature coronary artery disease F Gragnano, F Fimiani, M Di Maio, A Cesaro, G Limongelli, D Cattano, ... Internal and Emergency Medicine 14, 621-625, 2019 | 41 | 2019 |
| Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START … A Cesaro, F Gragnano, P Calabro, E Moscarella, F Santelli, F Fimiani, ... International Journal of Cardiology 345, 7-13, 2021 | 39 | 2021 |
| Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease P Calabro, F Gragnano, G Niccoli, R Marcucci, M Zimarino, ... Circulation 144 (16), 1323-1343, 2021 | 39 | 2021 |
| Low-dose ticagrelor in patients with high ischemic risk and previous myocardial infarction: a multicenter prospective real-world observational study A Cesaro, V Taglialatela, F Gragnano, E Moscarella, F Fimiani, M Conte, ... Journal of Cardiovascular Pharmacology 76 (2), 173-180, 2020 | 39 | 2020 |
| Phosphodiesterase-5 inhibitors improve clinical outcomes, exercise capacity and pulmonary hemodynamics in patients with heart failure with reduced left ventricular ejection … R De Vecchis, A Cesaro, C Ariano, A Giasi, C Cioppa Journal of Clinical Medicine Research 9 (6), 488, 2017 | 37 | 2017 |
| Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience F Gragnano, F Natale, F Fimiani, A Cesaro, S Sperlongano, M Crisci, ... Journal of Cardiovascular Medicine 19 (2), 75-77, 2018 | 36 | 2018 |
| Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity M Brancaccio, C Mennitti, A Cesaro, F Fimiani, E Moscarella, M Caiazza, ... International Journal of Environmental Research and Public Health 17 (24), 9424, 2020 | 35 | 2020 |
Paolo CalabroUniversity of Campania "Luigi Vanvitelli"Email verificata su unicampania.it
